Skip to Main Content

Temozolomide and Olaparib for O6-Methylguanine DNA Methyltransferase Promoter Hypermethylated Colorectal Cancer

Conditions

Colon | Rectum

Phase II

What is the purpose of this trial?

This is a Phase II, non-randomized, open-label study to evaluate temozolomide in combination with olaparib in patients with MGMT promoter hypermethylated advanced colorectal cancer.

  • Trial with
    Yale University
  • Start Date
    02/17/2020
  • End Date
    12/31/2021
Trial Image

For more information about this study, contact:

Christina Wiess

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/23/2020
  • Study HIC
    #2000026632